Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Sued by Investment Fund Over Pending eBioscience Deal

NEW YORK (GenomeWeb News) – Affymetrix is being sued by Tang Capital Partners over the Santa Clara, Calif.-based firm's proposed purchase of eBioscience.

In a document filed with the US Securities and Exchange Commission today, Affy said that the class action lawsuit, filed with the Superior Court of California, County of Santa Clara, alleges the purchase would constitute a fundamental change under the indenture that governs 3.50 percent senior convertible notes due 2038 held by Tang Capital.

Tang Capital, an investment fund based in San Diego, is seeking unspecified damages, temporary and permanent injunctive relief against completion of the purchase, and other remedies, Affy said. The company added that it believes the lawsuit is without merit and continues to work toward completing its eBioscience acquisition.

Affy's proposed $330 million buy of eBioscience was announced in November and was expected to be completed by the end of 2011. Earlier this week, Affy pushed the anticipated completion period to January 2012.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.